Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 20 of 30 for “"GnRH-a"”.
-
Ο ρόλος της χορήγησης GnRH-a στην αγγειογένεση της ενδομητρίωσης
… Gonadotrophin-releasing hormone-agonists (GnRH-a) are routinely used, especially preoperatively, in endometriosis. It would be of great interest to clarify which angiogenetic pathways are affected and, thereby, pave the way for further research into antiangiogenetic effects on …
-
Επίδραση της χορήγησης GnRH αγωνιστών στο ωοθηκικό περιβάλλον και τη γονιμότητα γυναικών που πάσχουν από ενδομητρίωση
Objective: To evaluate the effects of GnRH-a on women’s fertility with mild endometriosis, undergoing IVF-ET procedures. Design: Prospective, randomized, controlled trial. Setting: Three tertiary University Hospitals. Patients: Four hundred infertile women with mild endometriosis, documented …
-
The Effect of Hypothalamic Suppression and Caloric Restriction on Bone Strength and Geometry during Puberty
… 50, or two experimental groups; delayed puberty (GnRH-a, n=14) that received daily injections of gonadotropin releasing hormone antagonist (GnRH-a, 0.2cc, dosage 0.2mg*kg-1) or food restricted and delayed puberty (FR-G, n=8) that received daily injections of gonadotropin releasing hormone …
-
Role of gonadotropin-releasing hormone in the ovarian cells
… roles for gonadotropin-releasing hormone (GnRH) in reproductive tissues, the present study investigated role of GnRH in the ovarian cells. The GnRH and GnRH receptor (GnRHR) mRNA were expressed and autoregulated in a biphasic mariner by a GnRH agonist (GnRH-a) in human ovarian surface …
-
IDENTIFICATION OF MECHANISMS OF DELAYED PUBERTY ON BONE STRENGTH DEFICITS DURING DEVELOPMENT
… with gonadatropin releasing hormone antagonists (GnRH-a) and energy restriction (30%). Thirty-two female Sprague Dawley rats (21 to 22 days-of-age) were received from (Charles Rivers Laboratories, Wilmington, MA, USA) and housed individually at the Temple University Central Animal Facility (Temple …
-
Pheromonal stimulation of ovulation in female Hymenochirus curtipes
… water, gonadotropin releasing hormone agonist (GnRH-a) in water, and GnRH-a injected males. Ovulation was induced in females exposed to two of the variable conditions: GnRH-a injected males (87%) and uninjected-glandless males (85%). No other treatments induced ovulation at these levels, …
-
Πρόκληση ωοθυλακιορρηξίας για κύκλους με χρήση GNRH-a ανταγωνιστή, σε πτωχές και φυσιολογικές απαντήτριες, που υποβάλλονται σε εξωσωματική γονιμοποίηση ICSI. Συστηματική ανασκόπηση και μετα-ανάλυση τυχαιοποιημένων μελετών. Ανασκόπηση βιβλιογραφίας
… της εκλυτικής ορμόνης των γοναδοτροπινών (GnRH) και της ανθρώπινης χοριακής γοναδοτροπίνης (hCG)] μπορεί να βελτιώσει τον αριθμό των ωαρίων που ανακτώνται και των ποσοστών κλινικής κύησης σε άτομα με πτωχή ή φυσιολογική ανταπόκριση των ωοθηκών, που υποβάλλονται σε κύκλους εξωσωματικής …
-
Factors involved in the control of plasma thyroid hormone concentrations during an induced molt in the domestic hen
… of a gonadotropin releasing hormone agonist (GnRH-A; (D-Leu$\sp6$,Pro$\sp9$) -GnRH N-ethylamide), and compared with molt induced by FW. Hens were divided into three groups: (1) sham infused (controls); (2) molted by GnRH-A infusion (GnRH-A); or (3) molted by FW. Plasma was assayed for T$\sb4$, …
-
Time- and Dose-related Effects of a Gonadotropin-releasing Hormone Agonist and Dopamine Antagonist on Reproduction in the Northern Leopard Frog (Lithobates pipiens) and the Western Clawed Frog (Silurana tropicalis)
… of a gonadotropin-releasing hormone agonist (GnRH-A) (0.1 μg/g , 0.2 μg/g and 0.4 μg/g) alone and in combination with two doses of the selective dopamine receptor D2 antagonist metoclopramide (MET) (5 μg/g and 10 μg/g). Injected animals were allowed to breed in mesocosms in an outdoor field. …
-
ΕΠΙΠΕΔΑ ΟΙΣΤΡΑΔΙΟΛΗΣ, ΠΡΟΓΕΣΤΕΡΟΝΗΣ ΚΑΙ ΚΟΡΤΙΖΟΛΗΣ ΣΤΟ ΩΟΘΥΛΑΚΙΚΟ ΥΓΡΟ ΣΕ ΑΥΤΟΜΑΤΗ ΚΑΙ ΠΡΟΚΛΗΤΗ ΩΟΘΥΛΑΚΙΟΡΡΗΞΙΑ
… OF 42 WOMEN WHO RECEIVED GONADOTROPINS AND GNRH-A FOR INDUCTION OF OVULATION FOR IVF. THE CONTROL GROUP INCLUDED 23 NORMAL CYCLING WOMEN.AFTER EVALUATING OUR RESULTS THE FOLLOWING CONCLUSIONS CAN BE DRAWN: 1) SERUMESTRADIOL AND PROGESERONE SHOWED A STATISTICALLY HIGHLY SIGNIFICANT DIFFERENCE …
-
Studies on ovarian GnRH-R and GnRH mRNA, and the direct effects of GnRH on ovarian function in the bovine
… with respect to the intra-ovarian presence of GnRH-GnRH receptor system or direct effects of GnRH on ovarian function. Therefore, experiments were carried out to examine: if GnRH-R and GnRH mRNA are expressed in bovine ovary; the direct effects of a GnRH agonist (buserelin) on steroid hormone …
-
Biological Influences on the Cytogenetics of Early Human Development: An IVF Study
… with a gonadotrophin-releasing hormone analog (GnRH-a) during ovarian stimulation with human menopausal gonadotrophin (hMG) eliminated LH fluctuations and surges and all initiated cycles (n=32) proceeded to oocyte retrieval (OR) without complication. The cancellation rate (24/75; 32.0%) was …
-
Nanoclay Crosslinked pH-Sensitive Hydrogel for Rhythmic Hormone Delivery
Gonadotropin releasing hormone (GnRH) is secreted in rhythmic pulses every 1–2 hours. Disruption of this pulsatile release is associated with pathologies in reproductive function and sexual development. In order to approach an implantable, rhythmic delivery system for GnRH, a published prototype …
-
Die Bedeutung von Gonadotropin-Releasing-Hormon-Agonisten in der Fertilitätsprotektion von Frauen während einer zytotoxischen Therapie: eine prospektive Kohortenstudie
… medikamentösen Fertilitätsprotektion mittels GnRH-Agonisten bleibt die Evidenz kontrovers. Anhand der hier vorgestellten prospektiven Kohortenstudie mit 116 prämenopausalen Chemotherapie-Patientinnen im Alter von 13‑40 Jahren sollte die Wirksamkeit einer Fertilitätsprotektion mittels GnRH-a …
-
ΑΝΤΙΜΕΤΩΠΙΣΗ ΤΩΝ ΥΠΕΡΠΛΑΣΙΩΝ ΤΟΥ ΕΝΔΟΜΗΤΡΙΟΥ ΜΕ ΤΗ ΧΟΡΗΓΗΣΗ ΑΝΑΛΟΓΩΝ ΤΗΣ ΕΚΛΥΤΙΚΗΣ ΤΩΝ ΓΟΝΑΔΟΤΡΟΠΙΝΩΝ ΟΡΜΟΝΗΣ
… EXAMINE THE EFFECTIVENESS OF THE TREATMENT WITH GNRH - A IN PATIENTS WITH ENDOMETRIAL HYPERPLASIA. FIFTY SIX PATIENTS WITH HYPERPLASIA OF THE ENDOMETRIUM WERE ENROLLED IN THE TRIAL. THE PATIENTS WERE DIVIDED INTO THREE GROUPS: GROUP I, CONSISTED OF 39 PATIENTS WITH ADENOCYSTIC (SIMPLE) …
-
Generation of a FHV-1 Viral Vaccine Against Gonadotropin Releasing Hormone for Immunocontraception of Felines
… (EGFP), and Gonadotropin Releasing Hormone (GnRH). FliC has been shown to stimulate a heightened antibody response when antigens are expressed as fusion proteins with it. GnRH, a major reproductive hormone responsible for the development of testes and ovaries in felines, is the target of our …
-
Low Estrogen Model and Percent Lamellar Bone Pre and Post Puberty
… with gonadotropin releasing-hormone antagonist (GnRH-a)-- the Dose 1 group was injected with 1.25 mg/kg/dose daily (n=14), the Dose 2 was injected with 2.5 mg/kg/dose daily (n=14), and the Dose 3 group was injected with 5.0 mg/kg/dose, 5 days per week (n=13). All groups were sacrificed at Day 49. …
-
Ανοσολογικοί παράγοντες που σχετίζονται με την ενδομητρίωση
… in patients with endometriosis during a 6- month GnRH-a (triptorelin) course with and without add-back therapy. Patients with endometriosis stage I-IV were divided in two groups. Group A patients (n=20) were treated with triptorelin 3,75 mg for 6 months. Group B patients (n=20) were treated with …
-
Silica nanoparticles as adjuvants for novel vaccines : a combined immunological, simulation and physical characterisation study
… In this study gonadotrophin releasing hormone (GnRH), a fertility regulating self-peptide, was used as a model antigen applied to Stober silica nanoparticles (used as an adjuvant) in a vaccine formulation. It is proposed that an inorganic silica nanoparticle can act as a foreign carrier particle …
Page 1 of 2